-
Mashup Score: 6
Piers Patten, MBChB, MRCP, FRCPath, PhD, King’s College London, London, UK, discusses the complex issue of selecting a therapy approach for patients with chronic lymphocytic leukemia (CLL). As the number of available treatment options has increased in recent years, physicians now have several agents to choose from. Dr Patten highlights that, when selecting a treatment, there is a need to consider the nature of the patient’s disease, their medical history and comorbidities, and, importantly, their preferences. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA approves fidanacogene elaparvovec, a one-time gene therapy, for adult patients with hemophilia B - 4 day(s) ago
Read about the FDA approval of fidanacogene elaparvovec, a one-time gene therapy, for adults with hemophilia B.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16Phase II ANIMATE trial investigating PET response-adapted treatment using nivolumab in R/R cHL - 5 day(s) ago
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines the first data from the Phase II ANIMATE trial (NCT03337919) which is investigating the use of positron emission tomography (PET) response-adapted treatment using nivolumab in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The primary endpoint of the study is the overall response rate (ORR), which was not as high as investigators had anticipated. However, Prof. Collins highlights the chemosensitization phenomenon that occurred in patients and improved their response to subsequent treatments, including autologous stem cell transplantation (autoSCT). This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5The relationship between the gut microbiome and GvHD - 5 day(s) ago
Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, gives an overview of the relationship between the gut microbiome and graft-versus-host disease (GvHD). A loss of microbiome diversity, mainly due to broad-spectrum antibiotic use or damage to paneth cells, dysregulates immune cell function in the gut, leading to acute GvHD. This could be corrected through better antibiotic stewardship or with fecal microbiota transplantation (FMT). Prof. Holler also addresses the paradox of antibiotic use, which can be both beneficial and harmful in the context of GvHD. The relationship between the gut microbiome and GvHD is complex, and further research is required. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs - 6 day(s) ago
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia…
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VJHemOnc β The video journal of hematological oncology - 6 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
#SOHO2023 is taking place next week in Houston, TX!π We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a
-
-
Mashup Score: 0
Claire Harrison, MD, FRCP, FRCPath, Guyβs & St Thomasβ NHS Foundation Trust, London, UK, provides a comprehensive overview of the current key trials in the United Kingdom in the field of myeloproliferative neoplasms (MPN). In essential thrombocythemia (ET), bomedemstat and calreticulin-directed therapies are being investigated. For patients with polycythemia vera (PV), hepcidin agonists are being trialed for reducing venesection requirements and iron deficiency, and the MITHRIDATE study (NCT04116502) is comparing ruxolitinib to hydroxycarbamide or interferon as frontline therapy for high-risk patients. In myelofibrosis (MF), calreticulin-targeting therapies are also being assessed, and several ongoing trials, including FEDORA (ISRCTN88102629) and PROMise (ISRCTN12451433), are investigating combination therapies. Prof. Harrison also highlights the launch of the myMPNVoice app, which will allow patients to track symptoms and facilitate the collection of a large volume of real-world data.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VJHemOnc β The video journal of hematological oncology - 7 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
#SOHO2023 is taking place next week in Houston, TX!π We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a
-
-
Mashup Score: 1Current SoC for BPDCN and other emerging treatment options - 7 day(s) ago
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, summarizes the current standard of care (SoC) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp, a first-in-class CD123-targeted agent, is particularly efficacious for first-line adult patients with BPDCN. Dr Papayannidis highlights that allogeneic stem cell transplantation (alloSCT) is utilized in virtually all cases of BPDCN following standard chemotherapy regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2BSH 2024 | VJHemOnc - 8 day(s) ago
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. We use cookies to provide the best experience on our website. We also use third party
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
We had an amazing time at #BSH2024 and want to say a big thank you to @BritSocHaem for having us on-site!π Exclusive interviews from the meeting are already available to watch on our site, with many more to come! π₯ Watch here: π https://t.co/vVSV7VpUkv #HemOnc #Hematology https://t.co/LnT5jTyKKE
-
What are some of the key factors to consider when choosing a treatment option for patients with CLL? π€ We sat down with @piers_patten of @KingsCollegeLon at #BSH2024 to hear his thoughts: π₯ https://t.co/fUlKY1lTMU #CLLsm #Leukemia #Leusm #HemOnc @BritSocHaem